PHLDA2 and hepatocellular carcinoma: The remaining eight genes, including TNFSF8, CD3E, ITK, KLRD1, PRKCQ, TRAF3IP3, PHLDA2, and C11orf21, have not previously been reported to impact the clinical prognosis of HCC patients, and may have the potential to serve as new biomarkers for HCC.